Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BC2E
|
|||
| Former ID |
DAP001391
|
|||
| Drug Name |
Hydroxyflutamide
|
|||
| Synonyms |
HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H11F3N2O4
|
|||
| Canonical SMILES |
CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O
|
|||
| InChI |
1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
|
|||
| InChIKey |
YPQLFJODEKMJEF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 52806-53-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6098624, 7847014, 7888141, 8027016, 10224937, 14898038, 17388977, 44422573, 48425200, 50020267, 50373625, 53789400, 56314870, 57334991, 71855504, 85856702, 88814879, 93165971, 93580018, 93618743, 95690522, 103119153, 103169927, 103854968, 103919533, 104253499, 104405334, 117362536, 118046573, 124890318, 124890319, 124890320, 125230930, 125371524, 126644703, 126727266, 126729472, 129830005, 134213533, 134338599, 135047620, 135650359, 135692442, 137185104, 137237595, 140728616, 143492980, 144208402, 144213961, 152237015
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2862). | |||
| REF 2 | Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. | |||
| REF 3 | Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87. | |||
| REF 4 | Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.